Tomoko Ichiki

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc BNP molecular forms and processing by the cardiac serine protease corin
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Adv Clin Chem 61:1-31. 2013
  2. pmc Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota Electronic address
    JACC Heart Fail 3:715-23. 2015
  3. pmc Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications
    Tomoko Ichiki
    Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA Electronic address
    J Mol Cell Cardiol 75:199-205. 2014
  4. pmc Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States Electronic address
    Peptides 48:21-6. 2013
  5. pmc Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 304:R102-9. 2013
  6. doi request reprint Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, MN 55905, USA
    Clin Chem 57:40-7. 2011
  7. pmc CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e52422. 2012
  8. pmc The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 57:201-7. 2011
  9. doi request reprint M-atrial natriuretic peptide: a novel antihypertensive protein therapy
    Paul M McKie
    Mayo Clinic, Division of Cardiovascular Diseases, Rochester, MN 55905, USA
    Curr Hypertens Rep 14:62-9. 2012
  10. pmc Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 302:R292-9. 2012

Detail Information

Publications18

  1. pmc BNP molecular forms and processing by the cardiac serine protease corin
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Adv Clin Chem 61:1-31. 2013
    ..A potential impairment of proBNP1lo8 processing in HF may be linked to dysregulation of the convertase corin, which may offer therapeutic opportunities to control proBNPlo0s processing and its activation in HF...
  2. pmc Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota Electronic address
    JACC Heart Fail 3:715-23. 2015
    ..The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP)...
  3. pmc Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications
    Tomoko Ichiki
    Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA Electronic address
    J Mol Cell Cardiol 75:199-205. 2014
    ..We conclude that the failing LV is characterized by increased fibrosis and reduced CNP gene expression. LVAD support did not reverse Col deposition nor restore CNP production, suggesting a therapeutic opportunity for CD-NP. ..
  4. pmc Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States Electronic address
    Peptides 48:21-6. 2013
    ..These studies support the therapeutic potential of dual inhibition of NEP and ACE in the prevention of increased arterial ECP and atherogenesis which may be linked to the ANP/cGMP system...
  5. pmc Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 304:R102-9. 2013
    ..Selective changes of these NP convertases may have significance in the regulation of pro-NP processing and atrial remodeling in early stage HF...
  6. doi request reprint Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation
    Tomoko Ichiki
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, MN 55905, USA
    Clin Chem 57:40-7. 2011
    ..The corin gene is expressed in the human heart and kidney, but corin protein expression in the heart, kidney, and circulation, along with whether proBNP is processed by circulating corin, remains unknown...
  7. pmc CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e52422. 2012
    ..Taken together, this novel dual GC receptor activator may represent an innovative anti-fibrotic therapeutic agent...
  8. pmc The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 57:201-7. 2011
    ..Together, these studies provide new insights into myocardial aging and the relationship to the antifibrotic and antiproliferative peptide CNP...
  9. doi request reprint M-atrial natriuretic peptide: a novel antihypertensive protein therapy
    Paul M McKie
    Mayo Clinic, Division of Cardiovascular Diseases, Rochester, MN 55905, USA
    Curr Hypertens Rep 14:62-9. 2012
    ..M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension...
  10. pmc Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 302:R292-9. 2012
    ..Thus, these studies importantly advance the concept of a kidney-heart connection in the control of myocardial structure and function...
  11. pmc Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population
    S Jeson Sangaralingham
    From the Cardiorenal Research Laboratory S J S, P M M, T I, D M H, H H C, M M R, J C B, Divisions of Cardiovascular Diseases S J S, P M M, T I, D M H, H H C, M M R, R J R, J C B, and Biomedical Statistics and Informatics C G S, K R B, Mayo Clinic, Rochester, MN
    Hypertension 65:1187-94. 2015
    ..Together, these data from the general population highlight the potential value of CNP and support the need for additional studies to evaluate whether mechanisms regulating CNP could improve outcomes...
  12. pmc Cardiac micro-computed tomography imaging of the aging coronary vasculature
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Circ Cardiovasc Imaging 5:518-24. 2012
    ....
  13. pmc Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study
    Paul M McKie
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:1154-60. 2011
    ....
  14. pmc A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 56:1152-9. 2010
    ..These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension...
  15. pmc B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts
    Brenda K Huntley
    Cardiorenal Research Laboratory, Division of Cardiovascular Disease, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Cell Physiol 225:251-5. 2010
    ..Further, on uncoated plates, integrin alphavbeta3 blockade continued to potentiate the BNP/cGMP response. These studies suggest that both RGD containing ECM proteins and integrins may interact with BNP/NPR-A to modulate cGMP generation...
  16. pmc Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure
    Brenda K Huntley
    From the Cardiorenal Research Laboratory, Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN
    Circ Heart Fail 8:89-97. 2015
    ..Because BNP1-32 is deficient whereas proBNP1-108 is abundant in HF, we hypothesize that proBNP1-108 processing and degradation are impaired in HF patients ex vivo...
  17. pmc M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics
    Paul M McKie
    Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN
    J Am Heart Assoc 3:e000206. 2014
    ....
  18. pmc Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA Electronic address
    Peptides 76:108-14. 2016
    ....